Will anti-homosexuality bills in sub-Saharan Africa impede HIV research?
As sub-Saharan African countries introduce more anti-homosexuality bills, there are concerns they could create a barrier to the LGBTQI+ community…
All articles by Irena Maragkou
Irena Maragkou
Irena Maragkou is a Healthcare Researcher for Clinical Trials Arena and Pharmaceutical Technology based in London, UK. Irena previously worked in consulting at Deloitte’s Strategy, M&A and Analytics Department, focusing on projects in the Pharmaceutical and Healthcare Sector. She holds an MSci degree in Neuroscience from UCL.
-
-
Flexibility of alternative trial designs crucial for cell and gene therapy research
The traditional randomised controlled trial (RCT) model has been used for decades in drug development. Although it is considered the…
-
GLP1-RAs beyond obesity and diabetes: Is the sky the limit?
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have taken the type 2 diabetes and obesity market by storm. Outside of the pharmaceutical…
-
Diversity and ePROs: Still siloed concepts in the era of DCTs?
Decentralised clinical trials (DCTs) are often pinned as a silver bullet to increase a trial’s footprint and reach various populations…
-
Profit vs inquiry: Clash of objectives in academic and commercial trials
Academic institutions and commercial entities play an important role in drug development and improving human health. While both types of…
-
DCT Tracker: Are sponsors getting better at conducting DCTs?
The role of decentralised clinical trials (DCTs) in the clinical trial industry has shifted over the past few years. Moreover,…
-
Are restrictive LGBTQ+ bills in the US impacting inclusion in clinical trials?
More bills that restrict the LGBTQ+ community were passed in the US in 2022. Some of these bills make gender-affirming…
-
Should RCTs remain the gold standard?
Decades ago, regulators and clinical researchers deemed randomised controlled trials (RCTs) as the “gold standard” in clinical research, in a…
-
DCT Tracker: The most explored endpoints in decentralised clinical trials
After peaking during the Covid-19 pandemic, the clinical trial industry is re-evaluating the pros and cons of decentralised clinical trials…
-
A year of Russia’s war in Ukraine: who is winning the battle on clinical trials?
One year has passed since Russia rolled its tanks into neighbouring Ukraine. The conflict accounts for the sobering toll of…